Your browser doesn't support javascript.
loading
A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer.
Zhan, Gouling; Hu, Jianbing; Da, Shijian; Weng, Jie; Zhou, Chuanyi; Wen, Fang; Liu, Songlian; Fang, Fang; Shen, Erdong; Zhou, Qiang; Luo, Pan; Xu, Min; Zhan, Dahe; Su, Yuqi.
Afiliación
  • Zhan G; Department of Oncology, Yueyang Central Hospital, Yueyang, China.
  • Hu J; Department of Oncology, Third Xiangya Hospital, Central South University, Changsha, China.
  • Da S; Department of Oncology, Yueyang Central Hospital, Yueyang, China.
  • Weng J; Department of Oncology, Yueyang Central Hospital, Yueyang, China.
  • Zhou C; Department of Oncology, Yueyang Central Hospital, Yueyang, China.
  • Wen F; Department of Oncology, Yueyang People's Hospital, Yueyang, China.
  • Liu S; Department of Oncology, Yueyang Central Hospital, Yueyang, China.
  • Fang F; Department of Oncology, Yueyang Central Hospital, Yueyang, China.
  • Shen E; Department of Oncology, Yueyang Central Hospital, Yueyang, China.
  • Zhou Q; Department of Oncology, Yueyang Central Hospital, Yueyang, China.
  • Luo P; Department of Oncology, Yueyang Central Hospital, Yueyang, China.
  • Xu M; Department of Oncology, Yueyang Central Hospital, Yueyang, China.
  • Zhan D; Department of Hepatobiliary Surgery, Yueyang Central Hospital, Yueyang, China.
  • Su Y; Department of Oncology, Yueyang Central Hospital, Yueyang, China.
Front Endocrinol (Lausanne) ; 14: 1110624, 2023.
Article en En | MEDLINE | ID: mdl-36742383

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Tegafur Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Front Endocrinol (Lausanne) Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Tegafur Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Front Endocrinol (Lausanne) Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza